

Antidepressants - sCORE

Products Affected

- EMSAM PATCH 24 HOUR 12 MG/24HR TRANSDERMAL
- EMSAM PATCH 24 HOUR 6 MG/24HR TRANSDERMAL
- EMSAM PATCH 24 HOUR 9 MG/24HR TRANSDERMAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 120 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 20 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 40 MG ORAL
- FETZIMA CAPSULE EXTENDED RELEASE 24 HOUR 80 MG ORAL
- FETZIMA TITRATION CAPSULE ER 24 HOUR THERAPY PACK 20 & 40 MG ORAL
- SERTRALINE HCL CAPSULE 150 MG ORAL
- SERTRALINE HCL CAPSULE 200 MG ORAL

Details

Details	
Criteria	Trial of two generics of the following formulary products: bupropion, mirtazapine, citalopram, desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline (tablet or solution), venlafaxine. Approve for continuation of prior therapy.

Atypical Antipsychotics - sCORE

Products Affected

- CAPLYTA CAPSULE 42 MG ORAL
- FANAPT TABLET 1 MG ORAL
- FANAPT TABLET 10 MG ORAL
- FANAPT TABLET 12 MG ORAL
- FANAPT TABLET 2 MG ORAL
- FANAPT TABLET 4 MG ORAL
- FANAPT TABLET 6 MG ORAL
- FANAPT TABLET 8 MG ORAL
- FANAPT TITRATION PACK TABLET 1 & 2 & 4 & 6 MG ORAL
- LYBALVI TABLET 10-10 MG ORAL
- LYBALVI TABLET 15-10 MG ORAL
- LYBALVI TABLET 20-10 MG ORAL
- LYBALVI TABLET 5-10 MG ORAL
- VRAYLAR CAPSULE 1.5 MG ORAL
- VRAYLAR CAPSULE 3 MG ORAL
- VRAYLAR CAPSULE 4.5 MG ORAL
- VRAYLAR CAPSULE 6 MG ORAL
- VRAYLAR CAPSULE THERAPY PACK 1.5 & 3 MG ORAL

Details

Details	
Criteria	Trial of two of the following oral generic formulary atypical antipsychotic agents: aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone. Approve for continuation of prior therapy. Step requirement does not apply for Caplyta if request is for depressive episodes associated bipolar I or II disorder.

Glucagon- sCORE

Products Affected

- GLUCAGEN HYPOKIT SOLUTION
RECONSTITUTED 1 MG INJECTION

Details

Criteria	Trial of one of the following: Gvoke, Baqsimi, or Glucagon
-----------------	--

Invega Hafyera Therapy - sCORE

Products Affected

- INVEGA HAFYERA SUSPENSION
PREFILLED SYRINGE 1092 MG/3.5ML
INTRAMUSCULAR
- INVEGA HAFYERA SUSPENSION
PREFILLED SYRINGE 1560 MG/5ML
INTRAMUSCULAR

Details

Criteria	Trial of one of the following: Invega Sustenna or Invega Trinza. Step applies to new starts only. Approve for continuation of prior therapy.
-----------------	--

NAMZARIC - sCORE

Products Affected

- NAMZARIC CAPSULE ER 24 HOUR THERAPY PACK 7 & 14 & 21 & 28 -10 MG ORAL
- NAMZARIC CAPSULE EXTENDED RELEASE 24 HOUR 14-10 MG ORAL
- NAMZARIC CAPSULE EXTENDED RELEASE 24 HOUR 21-10 MG ORAL
- NAMZARIC CAPSULE EXTENDED RELEASE 24 HOUR 28-10 MG ORAL
- NAMZARIC CAPSULE EXTENDED RELEASE 24 HOUR 7-10 MG ORAL

Details

Details	
Criteria	Trial of generic memantine extended-release

PD agents - sCORE

Products Affected

- NEUPRO PATCH 24 HOUR 1 MG/24HR TRANSDERMAL
- NEUPRO PATCH 24 HOUR 2 MG/24HR TRANSDERMAL
- NEUPRO PATCH 24 HOUR 3 MG/24HR TRANSDERMAL
- NEUPRO PATCH 24 HOUR 4 MG/24HR TRANSDERMAL
- NEUPRO PATCH 24 HOUR 6 MG/24HR TRANSDERMAL
- NEUPRO PATCH 24 HOUR 8 MG/24HR TRANSDERMAL

Details

Details	
Criteria	Trial of one of the following generic formulary dopamine agonist agent: pramipexole, ropinirole

RELISTOR - sCORE

Products Affected

- RELISTOR SOLUTION 12 MG/0.6ML SUBCUTANEOUS
- RELISTOR SOLUTION 12 MG/0.6ML SUBCUTANEOUS (0.6ML SYRINGE)
- RELISTOR SOLUTION 8 MG/0.4ML SUBCUTANEOUS
- RELISTOR TABLET 150 MG ORAL

Details

Criteria	Trial of lubiprostone or lactulose
-----------------	------------------------------------

RYTARY - sSCORE

Products Affected

- RYTARY CAPSULE EXTENDED RELEASE 23.75-95 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 36.25-145 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 48.75-195 MG ORAL
- RYTARY CAPSULE EXTENDED RELEASE 61.25-245 MG ORAL

Details

Criteria	
	Trial of one generic carbidopa/levodopa containing formulation

Skin Cancer Agents - sCORE

Products Affected

- *diclofenac sodium gel 3 % external*
- PICATO GEL 0.015 % EXTERNAL
- PICATO GEL 0.05 % EXTERNAL

Details

Criteria	Trial of fluorouracil or imiquimod
-----------------	------------------------------------

Statins - sCORE

Products Affected

- LIVALO TABLET 1 MG ORAL
- LIVALO TABLET 2 MG ORAL
- LIVALO TABLET 4 MG ORAL

Details

Criteria	Trial of any one of the following generic formulary HMG-CoA reductase inhibitors (statin): atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin
-----------------	--

Index of Drugs

C

CAPLYTA CAPSULE 42 MG ORAL 2

D

diclofenac sodium gel 3 % external 9

E

EMSAM PATCH 24 HOUR 12 MG/24HR
TRANSDERMAL..... 1

EMSAM PATCH 24 HOUR 6 MG/24HR
TRANSDERMAL..... 1

EMSAM PATCH 24 HOUR 9 MG/24HR
TRANSDERMAL..... 1

F

FANAPT TABLET 1 MG ORAL..... 2

FANAPT TABLET 10 MG ORAL..... 2

FANAPT TABLET 12 MG ORAL..... 2

FANAPT TABLET 2 MG ORAL..... 2

FANAPT TABLET 4 MG ORAL..... 2

FANAPT TABLET 6 MG ORAL..... 2

FANAPT TABLET 8 MG ORAL..... 2

FANAPT TITRATION PACK TABLET 1 & 2
& 4 & 6 MG ORAL..... 2

FETZIMA CAPSULE EXTENDED
RELEASE 24 HOUR 120 MG ORAL 1

FETZIMA CAPSULE EXTENDED
RELEASE 24 HOUR 20 MG ORAL 1

FETZIMA CAPSULE EXTENDED
RELEASE 24 HOUR 40 MG ORAL 1

FETZIMA CAPSULE EXTENDED
RELEASE 24 HOUR 80 MG ORAL 1

FETZIMA TITRATION CAPSULE ER 24
HOUR THERAPY PACK 20 & 40 MG
ORAL 1

G

GLUCAGEN HYPOKIT SOLUTION
RECONSTITUTED 1 MG INJECTION... 3

I

INVEGA HAFYERA SUSPENSION
PREFILLED SYRINGE 1092 MG/3.5ML
INTRAMUSCULAR 4

INVEGA HAFYERA SUSPENSION
PREFILLED SYRINGE 1560 MG/5ML
INTRAMUSCULAR 4

L

LIVALO TABLET 1 MG ORAL 10

LIVALO TABLET 2 MG ORAL 10

LIVALO TABLET 4 MG ORAL 10

LYBALVI TABLET 10-10 MG ORAL 2

LYBALVI TABLET 15-10 MG ORAL 2

Formulary ID 22332, Version 12

Effective Date: 05/01/2022

Last Updated: April 2022

LYBALVI TABLET 20-10 MG ORAL.....2

LYBALVI TABLET 5-10 MG ORAL.....2

N

NAMZARIC CAPSULE ER 24 HOUR
THERAPY PACK 7 & 14 & 21 & 28 -10
MG ORAL5

NAMZARIC CAPSULE EXTENDED
RELEASE 24 HOUR 14-10 MG ORAL...5

NAMZARIC CAPSULE EXTENDED
RELEASE 24 HOUR 21-10 MG ORAL...5

NAMZARIC CAPSULE EXTENDED
RELEASE 24 HOUR 28-10 MG ORAL...5

NAMZARIC CAPSULE EXTENDED
RELEASE 24 HOUR 7-10 MG ORAL.....5

NEUPRO PATCH 24 HOUR 1 MG/24HR
TRANSDERMAL.....6

NEUPRO PATCH 24 HOUR 2 MG/24HR
TRANSDERMAL.....6

NEUPRO PATCH 24 HOUR 3 MG/24HR
TRANSDERMAL.....6

NEUPRO PATCH 24 HOUR 4 MG/24HR
TRANSDERMAL.....6

NEUPRO PATCH 24 HOUR 6 MG/24HR
TRANSDERMAL.....6

NEUPRO PATCH 24 HOUR 8 MG/24HR
TRANSDERMAL.....6

P

PICATO GEL 0.015 % EXTERNAL9

PICATO GEL 0.05 % EXTERNAL9

R

RELISTOR SOLUTION 12 MG/0.6ML
SUBCUTANEOUS.....7

RELISTOR SOLUTION 12 MG/0.6ML
SUBCUTANEOUS (0.6ML SYRINGE) ...7

RELISTOR SOLUTION 8 MG/0.4ML
SUBCUTANEOUS.....7

RELISTOR TABLET 150 MG ORAL7

RYTARY CAPSULE EXTENDED RELEASE
23.75-95 MG ORAL8

RYTARY CAPSULE EXTENDED RELEASE
36.25-145 MG ORAL8

RYTARY CAPSULE EXTENDED RELEASE
48.75-195 MG ORAL8

RYTARY CAPSULE EXTENDED RELEASE
61.25-245 MG ORAL8

S

SERTRALINE HCL CAPSULE 150 MG
ORAL.....1

SERTRALINE HCL CAPSULE 200 MG
ORAL 1

V

VRAYLAR CAPSULE 1.5 MG ORAL 2
VRAYLAR CAPSULE 3 MG ORAL 2

VRAYLAR CAPSULE 4.5 MG ORAL2
VRAYLAR CAPSULE 6 MG ORAL2
VRAYLAR CAPSULE THERAPY PACK 1.5
& 3 MG ORAL.....2